摘要
目的:评估阿托伐他汀联合地塞米松对慢性硬膜下血肿(chronic subdural hematoma,CSDH)患者钻孔引流术后复发的影响。方法:选取2015年5月-2017年2月中信惠州医院神经外科收治的CSDH患者60例作为研究对象,根据随机数字表法将其分为观察组与对照组,每组30例。观察组钻孔引流术后给予阿托伐他汀联合地塞米松治疗,对照组钻孔引流术后单纯给予阿托伐他汀治疗。记录两组治疗前后格拉斯哥昏迷评分法(GCS)评分、日常生活能力(ADL)评分、治疗总有效率、复发率及不良反应发生情况并进行比较。结果:治疗前,两组GCS、ADL评分比较,差异均无统计学意义(P>0.05)。治疗后,两组GCS、ADL评分较治疗前均显著升高,且观察组升高更为明显,差异均有统计学意义(P<0.05);观察组治疗总有效率96.67%显著高于对照组83.33%,差异有统计学意义(X^2=2.765,P<0.05)。随访3个月内,观察组复发率3.33%显著低于对照组的13.33%,差异有统计学意义(X^2=6.289,P<0.05)。在治疗过程中两组均无明显不良反应。结论:阿托伐他汀联合地塞米松治疗CSDH疗效可靠,神经功能以及日常生活能力均显著改善,且术后血肿复发率低,值得在临床进行推广应用。
Objective:To discuss the efficacy of Atorvastatin combined with Dexamethasone on recurrence of patients with chronic subdural hematoma(CSDH)after drilling and drainage.Method:A total of 60 patients with CSDH in our hospital form May 2015 to February 2017 were divided into the observation group(30cases)and the control group(30cases)according to the random number table method.The observation group was treated with Atorvastatin and Dexamethasone after drilling and drainage,while the control group was treated with Atorvastatin after drilling and drainage.GCS scores,ADL scores,total effective rate,recurrence rate and adverse reactions of two groups were compared.Result:Before treatment,the difference of GCS and ADL scores between two groups were not obvious(P>0.05).After treatment,GCS and ADL scores of two groups were significantly increased,and the observation group more significantly increased,the differences were statistically significance(P<0.05).The total effective rate of the observation group(96.67%)was significantly higher than that of the control group(83.33%),the difference was statistically significant(x2=2.765,P<0.05).After 3 months follow-up,the recurrence rate of the observation group(3.33%)was significantly lower than that of the control group(13.33%),the difference was statistical significance(x2=6.289,P<0.05).In the course of treatment,there was no obvious adverse reactions in two groups.Conclusion:Atorvastatin combined with Dexamethasone in the treatment of CSDH is reliable,the neurological function and daily living ability are significantly improved,and the postoperative hematoma recurrence rate is low,so it is worth of popularizing in clinical practice.
作者
王东挺
张学军
梁伟
WANG Dongting;ZHANG Xuejun;LIANG Wei(Zhongxin Huizhou Hospital,Huizhou 516006,China)
出处
《中国医学创新》
CAS
2018年第8期54-57,共4页
Medical Innovation of China
基金
惠州市科技计划项目(2017Y193)
